TD Asset Management
LENZ

TD Asset Management’s LENZ Therapeutics LENZ Stock Holding History

TD Asset Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-24,610
Closed -$225K – 1329
2026
Q1 		$225K Sell
24,610
-2,368
-9% -$33.3K ﹤0.01% 1219
2025
Q4 		$432K Sell
26,978
-4,422
-14% -$129K ﹤0.01% 1183
2025
Q3 		$1.46M Buy
+31,400
New +$1.15M ﹤0.01% 1026
2025
Q2 		– Sell
-34,828
Closed -$895K – 1265
2025
Q1 		$895K Sell
34,828
-68,172
-66% -$1.68M ﹤0.01% 1081
2024
Q4 		$2.97M Buy
103,000
+74,690
+264% +$2.28M ﹤0.01% 899
2024
Q3 		$681K Buy
+28,310
New +$628K ﹤0.01% 1255

Other funds holding LENZ

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

TD Asset Management's LENZ Position: Q2 2026 in Review

TD Asset Management sold out of LENZ Therapeutics (LENZ) in Q2 2026, closing a stake of 24,610 shares — an estimated $225K sold.

TD Asset Management first reported a position in LENZ in Q3 2024 and held it in 6 quarters. The position peaked at $2.97M in Q4 2024. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • TD Asset Management reported no remaining LENZ Therapeutics position as of Q2 2026 after selling out during the quarter.
  • TD Asset Management sold 24,610 LENZ Therapeutics shares in Q2 2026, an estimated $225K.
  • TD Asset Management first reported a position in LENZ Therapeutics in Q3 2024 and held it in 6 quarters.
  • TD Asset Management's LENZ Therapeutics position peaked at $2.97M in Q4 2024.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on TD Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.